Endologix price target lowered to $17 from $20 at Stifel Stifel reduced its price target on Endologix after the company reported lower than expected Q4 revenue and provided lower than expected 2014 revenue guidance. However, the firm remains confident that the company can return to 20%+ sustainable growth next year, and keeps a Buy rating on the shares.
News For ELGX From The Last 14 Days
Check below for free stories on ELGX the last two weeks.
On The Fly: Analyst Upgrade Summary CBOE Holdings (CBOE) upgraded to Outperform from Market Perform at Raymond James... Silver Bay Realty (SBY) upgraded to Overweight from Neutral at JPMorgan... U.S. Steel (X) upgraded to Outperform from Underperform at Credit Suisse... Endologix (ELGX) upgraded to Buy from Neutral at BTIG... Texas Roadhouse (TXRH) upgraded to Overweight from Equal Weight at Stephens... WPX Energy (WPX) upgraded to Outperform from Sector Perform at Howard Weil... Nomura (NMR) upgraded to Outperform from Neutral at Credit Suisse.